HarmoniaMentis
Resources vault
This promotional website is managed and funded by Angelini Pharma and is intended for UK and Ireland healthcare professionals only.
A comprehensive library of resources designed to support your clinical practice and patients prescribed ONTOZRY®. All resources are available in print and digital versions. To order print copies, please email info@angelinipharma.com.
For healthcare professionals - Resources designed for your clinical practice
A guide for healthcare professionals
This guide has been developed to help you support your patients with epilepsy whose focal-onset seizures are drug resistant and have been prescribed ONTOZRY®, as well as information on how you can support your patients during treatment.
Click here to access the digital version.
Managing drug–drug interactions
Practical insights on managing drug–drug interactions with ONTOZRY® to optimise treatment outcomes in adults with focal-onset epilepsy.
Click here to access the digital version.
How to initiate your patients
A practical guide outlining the steps to initiate ONTOZRY® in adults with focal-onset epilepsy, including titration, dosing and co-medication.
Click here to access the digital version.
Titration guide
The titration guide provides practical, evidence-based strategies to optimise seizure control and treatment tolerability in focal-onset epilepsy.
Click here to access the digital version.
Updated NICE Technology Appraisal
NICE updated its guidance on ONTOZRY® in May 2025 – read the recommendations in this summary leaflet.
Click here to access the digital version.
For patients – Resources designed for your patients prescribed ONTOZRY®
Introduction guide
This guide is for people who have been prescribed ONTOZRY® as an add-on to their existing epilepsy medicine. It has been designed to support your patients during treatment and answer frequently asked questions.
Click here to access the digital version.
Titration diary
The ONTOZRY® titration diary is a practical tool to help your patients through the start of treatment by tracking doses, seizures and side effects.
Click here to access the digital version.
United Kingdom: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti–epileptic medicinal products.1
Republic of Ireland: ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal–onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti–epileptic medicinal products.1
1. ONTOZRY® Summary of Product Characteristics. United Kingdom and European Union.
MAT-UKI-0222-P | September 2025
